Pharmaceutical News and Articles

ADHD Athletes Take Longer To Recover From Concussion

THURSDAY, May 1, 2025 High school athletes with ADHD take longer to recover from a sport-related concussion, a new study says. Those with a concussion took abou

Ozempic Can Treat Fatty Liver Disease

The cutting-edge weight-loss drug Ozempic Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taki

Epilepsy, Anxiety Meds Don't Increase Suicide Risk

THURSDAY, May 1, 2025 A class of drugs used to treat epilepsy, nerve pain and anxiety do not appear to increase a person s risk of self-harm, a major new study

Florida Moves to Ban Fluoride in Drinking Water

THURSDAY, May 1, 2025 Florida state lawmakers have approved a bill to ban the addition of fluoride to public drinking water, a move that public health experts s

Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application for Elamipretide

Burnout and Stress Continue to Plague the Nursing Profession

The nursing workforce remains under immense pressure due to stress, burnout, and persistent short staffing, according to a report released by Cross Country Heal

NIH Study Reveals How Inflammation Makes Touch Painful

Researchers at the National Institutes of Health (NIH) have discovered clues as to how our bodies turn sensations such as heat and touch into signals sent to th

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer

LAS VEGAS, April 26, 2025 Johnson Johnson (NYSE JNJ) today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200 an intrav

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer Inc. (NYSE PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in co

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC

LAS VEGAS, April 26, 2025 Johnson Johnson (NYSE JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 an intravesi